Table 3.
Prescribers’ Level of Concern about Antipsychotic Polypharmacy (Rating 0–10).
| Degree to which Scenario Discourages Antipsychotic Polypharmacy (0–10) | Total (N=44) | High APP (>10%) (N=21 |
Low APP (≤ 10%) (N=23) |
F-Value | P-value |
|---|---|---|---|---|---|
| General Concern | |||||
| How problematic is antipsychotic polypharmacy | 5.0±1.9 | 4.3±2.0 | 5.7±1.7 | 5.73 | 0.021 |
| Clinical scenario | |||||
| Potential for higher chronic adverse events | 7.6±2.0 | 7.2±2.1 | 7.9±1.8 | 1.06 | 0.31 |
| Lack of evidence base | 7.1±2.2 | 6.7±1.9 | 7.3±2.5 | 0.76 | 0.39 |
| Increased risk of non-adherence | 6.7±2.3 | 6.0±2.5 | 7.3±2.1 | 3.17 | 0.082 |
| Potential for higher mortality | 6.7±3.2 | 6.3±3.4 | 7.1±3.0 | 0.57 | 0.45 |
| Potential drug-drug interactions | 6.6±2.7 | 6.6±2.5 | 6.5±2.8 | 0.027 | 0.87 |
| Potential for higher acute adverse events | 6.5±2.4 | 6.4±2.7 | 6.6±2.1 | 0.17 | 0.68 |
| Difficulty determining cause and effect | 6.4±2.4 | 5.9±2.2 | 6.8±2.5 | 1.42 | 0.24 |
| Increased cost | 4.9±2.5 | 5.1±2.3 | 4.8±2.6 | 0.23 | 0.63 |
| Higher total dosage of AP | 4.2±2.9 | 4.0±2.7 | 4.3±3.1 | 0.056 | 0.81 |
APP: Antipsychotic Polypharmacy Prescriber